Ultragenyx Pharma Reports $173M in Third-Quarter Revenue
Story updates
09:02:03 PM UTC
SquawkNews
Ultragenyx Pharma 3Q Loss/Shr $1.16 >RARE
09:02:03 PM UTC
SquawkNews
Ultragenyx Pharma 3Q Loss $118M >RARE
09:02:23 PM UTC
SquawkNews
Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue
09:10:19 PM UTC
SquawkNews
Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 millionGENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarterTwo Priority Review Vouchers (PRVs) under agreement for combined sales price of $413 millionSubstantial reduction of expe…